Immune checkpoint inhibitor treatment in patients with oncogene-addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion-Reference-Cited by-同舟云学术

Immune checkpoint inhibitor treatment in patients with oncogene-addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion

Published:2019 Issue:3 Volume:4 Page:e000498
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Berghoff Anna S.,Bellosillo Beatriz,Caux Christophe,de Langen Adrianus,Mazieres Julien,Normanno Nicola,Preusser Matthias,Provencio Mariano,Rojo Federico,Wolf Jurgen,Zielinski Christoph C.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference83 articles.

1. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative thoracic intergroup (IFCT);Barlesi;The Lancet,2016

2. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†;Novello;Ann Oncol,2016

3. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer;Gandhi;N Engl J Med,2018

4. Acquired resistance to targeted therapies against oncogene-driven non–small-cell lung cancer: approach to subtyping progressive disease and clinical implications;Gandara;Clinical Lung Cancer,2014

5. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma;Schadendorf;JCO,2015

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of PD-L1 expression on the efficacy of first-line crizotinib in advanced ROS1-rearranged NSCLC;Lung Cancer;2024-08

2. Further knowledge and developments in resistance mechanisms to immune checkpoint inhibitors;Frontiers in Immunology;2024-06-05

3. Compromised Outcomes in Stage IV Non–Small-Cell Lung Cancer With Actionable Mutations Initially Treated Without Tyrosine Kinase Inhibitors: A Retrospective Analysis of Real-World Data;JCO Oncology Practice;2024-01

4. First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC;New England Journal of Medicine;2023-11-16

5. Poor response to sintilimab plus chemotherapy in a pulmonary epithelioid hemangioendothelioma patient: a case report;Immunotherapy;2023-02